Fox Chase Cancer Center News

PHILADELPHIA (May 4, 2020)—As COVID-19 continues to put a strain on hospitals, numerous restaurants, companies, and individuals have stepped up to donate food and other items to health care workers on the frontlines of the pandemic.

Fox Chase Cancer Center has received multiple donations from the community as staff continue to go above and beyond in caring for patients.

Philadelphia Magazine named forty-four Fox Chase Cancer Center physicians to their “Top Doctors” list for 2020. 

PHILADELPHIA (April 30, 2020)—In a study published today, researchers at Fox Chase Cancer Center were able to determine that the BRCA1 gene has two distinct and equally important functions in the process of DNA repair, a finding which sheds light on the response and resistance of cancers to certain chemotherapies. The findings have implications for cancer therapy because drugs known as PARP inhibitors successfully treat BRCA1-mutant breast and ovarian cancers

PHILADELPHIA (April 27, 2020) – Researchers at Fox Chase Cancer Center recently published a series of articles in Cancer Prevention Research, a journal of the American Association for Cancer Research, honoring Paul F. Engstrom, MD, FACP, and his role as a pioneer in the field.

PHILADEPHIA (April 27, 2020) – Two Fox Chase Cancer Center doctors were honored by PAMED: Sanjay S. Reddy, MD, FACS, associate professor in the Department of Surgical Oncology, and Namrata “Neena” Vijayvergia, MD, assistant chief of gastrointestinal medical oncology in the Department of Hematology/Oncology.

PHILADELPHIA (April 24, 2020) – Christian Koch, MD, PhD, FACP, MACE, a professor in the Department of Medicine and director for the Division of Endocrinology at Fox Chase Cancer Center, was recently named a review editor for Frontiers in Cancer Endocrinology, a specialty section in the journal Frontiers in Endocrinology.

PHILADELPHIA (April 23, 2020)— The grant was awarded to Israel Cañadas, PhD by the Lung Cancer Research Foundation to study how different cancer cells within a tumor may affect the environment around it and the tumor’s response to therapy.

PHILADELPHIA (April 21, 2020)—A clinical trial headed by Fox Chase Cancer Center physicians has found that patients with certain common benign, spontaneous kidney tumors saw a marked decrease in tumor volume after being treated with the drug everolimus, also known by its brand name, Afinitor. Until this study, there were no data on whether the drug was effective and safe for patients with the tumors who don’t have angiomyolipomas.